Pinnacle Associates Ltd. boosted its position in Sanofi (NASDAQ:SNY – Get Rating) by 6.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,250 shares of the company’s stock after acquiring an additional 978 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Sanofi were worth $580,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Fairfield Bush & CO. acquired a new stake in Sanofi in the first quarter valued at approximately $26,000. Eagle Bay Advisors LLC purchased a new position in Sanofi in the second quarter valued at approximately $28,000. Ronald Blue Trust Inc. purchased a new position in Sanofi in the second quarter valued at approximately $34,000. Destiny Wealth Partners LLC increased its stake in Sanofi by 162.0% in the second quarter. Destiny Wealth Partners LLC now owns 676 shares of the company’s stock valued at $34,000 after purchasing an additional 418 shares during the last quarter. Finally, Bogart Wealth LLC increased its stake in Sanofi by 740.7% in the second quarter. Bogart Wealth LLC now owns 681 shares of the company’s stock valued at $34,000 after purchasing an additional 600 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.
Sanofi Stock Performance
NASDAQ:SNY opened at $49.27 on Tuesday. The firm’s fifty day moving average price is $46.54 and its 200 day moving average price is $42.38. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The firm has a market cap of $124.90 billion, a price-to-earnings ratio of 17.85, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56.
Wall Street Analysts Forecast Growth
SNY has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of Sanofi in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, December 16th. They set a “buy” rating on the stock. Barclays lowered their target price on shares of Sanofi from €105.00 ($114.13) to €85.00 ($92.39) and set an “equal weight” rating on the stock in a research report on Friday, October 14th. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, December 2nd. Finally, Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research report on Tuesday, December 13th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- $2,000 at Alphabet’s YouTube Purchase: You’d Be Up This Much.
- Michael Burry is Bearish on Stocks Again and Heres Why
- Is Macau a Sinking Ship for Wynn Resorts?
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.